Spots Global Cancer Trial Database for Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Official Title: A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Study ID: NCT06433609
Conditions
Study Description
Brief Summary: Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811 and SHR-A1921 combined with adebrelimab in HER2-negative advanced breast cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Beijing GoBroad Hospital, Beijing, Beijing, China
Contact Details
Name: Yang Ke
Affiliation: Beijing GoBroad Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
